This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 178 |
mg ml | 120 |
immune response | 111 |
room temperature | 105 |
virus infection | 104 |
lung injury | 94 |
mast cells | 92 |
immune responses | 88 |
respiratory syndrome | 80 |
gene expression | 76 |
pr virus | 72 |
control group | 71 |
infected cells | 70 |
pbs group | 70 |
pref alum | 69 |
acute respiratory | 69 |
virus particles | 68 |
mg kg | 66 |
sirna nanoparticles | 66 |
three times | 64 |
previously described | 64 |
neutralizing antibody | 62 |
body weight | 60 |
flow cytometry | 60 |
airway epithelia | 60 |
infected mice | 59 |
pref advax | 56 |
honey bee | 54 |
immunized mice | 52 |
monoclonal antibodies | 51 |
epithelial cells | 50 |
hib crude | 50 |
severe acute | 48 |
dna vaccine | 47 |
cord uid | 47 |
doc id | 47 |
secondary antibody | 47 |
amino acid | 45 |
acute lung | 44 |
egg yolk | 42 |
negative control | 42 |
mouse model | 42 |
neutralizing antibodies | 42 |
iav entry | 42 |
igg liposomes | 41 |
immune system | 40 |
sirna nanoparticle | 40 |
escherichia coli | 40 |
spike protein | 39 |
buffered saline | 39 |
western blot | 39 |
respiratory syncytial | 39 |
significantly higher | 39 |
lung tissue | 39 |
mast cell | 38 |
performed using | 38 |
antiviral activity | 38 |
syncytial virus | 38 |
antibody titers | 37 |
described previously | 37 |
inflamed lungs | 36 |
injured lungs | 36 |
syndrome coronavirus | 35 |
host cell | 35 |
growth factor | 35 |
dna vaccines | 34 |
ind entry | 34 |
serum samples | 34 |
protein expression | 34 |
washed three | 34 |
influenza viruses | 33 |
middle east | 33 |
cell entry | 33 |
bovine serum | 32 |
cell culture | 32 |
pbs containing | 32 |
transmissible gastroenteritis | 32 |
tgev infection | 32 |
expression vector | 32 |
thermo fisher | 32 |
innate immune | 31 |
ptm buffer | 31 |
east respiratory | 31 |
inflammatory response | 31 |
lpeg sirna | 31 |
previous studies | 31 |
monoclonal antibody | 30 |
rabies virus | 30 |
equine antisera | 30 |
fisher scientific | 29 |
well plates | 29 |
signaling pathways | 28 |
treated groups | 28 |
fasciola hepatica | 28 |
plasmid dna | 27 |
additional file | 27 |
free virus | 27 |
target cells | 27 |
significant differences | 27 |
bovine colostrum | 26 |
influenza infection | 26 |
time pcr | 26 |
respiratory tract | 25 |
pbs controls | 25 |
immune cells | 25 |
macromolecular prodrugs | 25 |
molecular weight | 25 |
statistically significant | 25 |
days post | 25 |
marginated neutrophils | 25 |
viral rna | 25 |
cell line | 25 |
control mice | 25 |
pr pbs | 24 |
cell lysate | 24 |
hela cells | 24 |
goat anti | 24 |
weight loss | 24 |
antibody response | 24 |
virus titers | 24 |
chinese herbs | 24 |
igg antibodies | 24 |
specific antibodies | 24 |
drug delivery | 23 |
mouse igg | 23 |
cells expressing | 23 |
hibiscus tea | 23 |
viral infection | 23 |
cryptosporidium parvum | 23 |
human airway | 23 |
significant difference | 23 |
present study | 23 |
treated control | 23 |
analyzed using | 23 |
viral load | 23 |
cell surface | 23 |
treated mice | 23 |
virus replication | 23 |
spinal cord | 23 |
time point | 22 |
specific igg | 22 |
electron microscopy | 22 |
mg chinese | 22 |
large subunit | 22 |
time points | 22 |
sa mix | 22 |
phage display | 22 |
vibrating mesh | 22 |
hibiscus acid | 22 |
recombinant lactobacillus | 22 |
inflammatory cytokines | 22 |
statistical significance | 22 |
culture medium | 22 |
honey bees | 22 |
com scientificreports | 22 |
per group | 22 |
independent experiments | 22 |
ebola virus | 22 |
viral replication | 22 |
lymph nodes | 22 |
hepatitis virus | 22 |
per mouse | 21 |
viral particles | 21 |
sialic acid | 21 |
elisa plates | 21 |
previously reported | 21 |
viral antigen | 21 |
th th | 21 |
high levels | 21 |
protein concentration | 21 |
treated group | 21 |
campylobacter jejuni | 21 |
thermofisher scientific | 21 |
mouse hepatitis | 21 |
significantly lower | 21 |
acute inflammatory | 21 |
respiratory distress | 21 |
coli lysate | 21 |
cells infected | 20 |
total rna | 20 |
cfu ml | 20 |
btv wt | 20 |
distress syndrome | 20 |
cell suspensions | 20 |
mice immunized | 20 |
vaccinated mice | 20 |
lactobacillus vaccine | 20 |
ex vivo | 20 |
cell activation | 20 |
blood samples | 20 |
mucosal immune | 20 |
pg ml | 20 |
entry assay | 20 |
acid aspiration | 20 |
mice treated | 20 |
cns resident | 20 |
final concentration | 20 |
spectrum antiviral | 20 |
clinical symptoms | 20 |
side effects | 20 |
alexa fluor | 19 |
trcwp igy | 19 |
positive cells | 19 |
sigma aldrich | 19 |
treated animals | 19 |
oral infection | 19 |
gastroenteritis virus | 19 |
positive control | 19 |
tissue culture | 19 |
bd biosciences | 19 |
avian influenza | 19 |
low ph | 19 |
prophylactic activity | 19 |
shiga toxin | 19 |
immunosorbent assay | 19 |
survival rate | 19 |
enveloped viruses | 19 |
mucus production | 19 |
quantitative pcr | 19 |
control groups | 19 |
serum albumin | 19 |
novel coronavirus | 19 |
treated pr | 19 |
day post | 19 |
phosphate buffered | 19 |
apical surface | 19 |
results suggest | 19 |
highly pathogenic | 19 |
entry pathway | 19 |
well plate | 19 |
human lungs | 18 |
inflammatory lung | 18 |
mice infected | 18 |
sero elisa | 18 |
cell wall | 18 |
three independent | 18 |
pneumococcal pneumonia | 18 |
pbs control | 18 |
protective immunity | 18 |
protective effect | 18 |
western blotting | 18 |
linked immunosorbent | 18 |
vaccinated group | 18 |
injured mice | 18 |
plasma membrane | 18 |
cell lines | 18 |
human mast | 18 |
infected animals | 18 |
igf mrna | 18 |
washed twice | 18 |
sars coronavirus | 18 |
geometric mean | 18 |
adaptive immune | 18 |
rsv infection | 18 |
results indicate | 18 |
inhibitory effect | 18 |
conjugated anti | 18 |
lymph node | 18 |
guinea pigs | 18 |
alum immunization | 18 |
clinical trials | 18 |
cell types | 18 |
pref alone | 18 |
pr infection | 17 |
negative controls | 17 |
binding affinity | 17 |
significantly decreased | 17 |
photon excitation | 17 |
bee viruses | 17 |
results show | 17 |
acidic hib | 17 |
blocking agents | 17 |
indirect elisa | 17 |
bluetongue virus | 17 |
antibody fragments | 17 |
treatment groups | 17 |
antibody responses | 17 |
host cells | 17 |
expression levels | 17 |
fetal bovine | 17 |
light chain | 16 |
elisa assay | 16 |
ha head | 16 |
molar mass | 16 |
resident microglia | 16 |
bal fluid | 16 |
inflammatory responses | 16 |
paralysis virus | 16 |
blot analysis | 16 |
dextran nanogels | 16 |
ct values | 16 |
infectious bronchitis | 16 |
btv unag | 16 |
cell lysates | 16 |
purified rubisco | 16 |
world health | 16 |
results showed | 16 |
streptococcus pneumoniae | 16 |
drug release | 16 |
supplementary table | 16 |
surface expression | 16 |
entry pathways | 16 |
trna lys | 16 |
vector dna | 16 |
flow cytometer | 16 |
commonly used | 16 |
empty expression | 16 |
standard curve | 16 |
pr ppp | 16 |
significant changes | 15 |
day postinfection | 15 |
immunodeficiency virus | 15 |
spike proteins | 15 |
plate reader | 15 |
also observed | 15 |
rabbit igg | 15 |
specific antibody | 15 |
confocal microscopy | 15 |
specific igy | 15 |
pbs buffer | 15 |
animal care | 15 |
incubated overnight | 15 |
group viii | 15 |
effector cells | 15 |
health organization | 15 |
btv ns | 15 |
igf protein | 15 |
mesh nebuliser | 15 |
like growth | 15 |
data indicate | 15 |
human immunodeficiency | 15 |
swinepox virus | 15 |
pulmonary inflammation | 15 |
antiviral agents | 15 |
horseradish peroxidase | 15 |
acute sars | 15 |
taken together | 15 |
transport medium | 15 |
virus activity | 15 |
detected using | 15 |
env gene | 15 |
mesenteric lymph | 15 |
antibody production | 15 |
rabbit anti | 15 |
copy numbers | 15 |
pr igf | 14 |
albumin nps | 14 |
virus entry | 14 |
mapk signaling | 14 |
campylobacter infection | 14 |
post infection | 14 |
important role | 14 |
influenza vaccine | 14 |
reactive antibodies | 14 |
th vectors | 14 |
aspiration acute | 14 |
chicken egg | 14 |
chemical industries | 14 |
green fluorescent | 14 |
suction window | 14 |
fi eld | 14 |
dep entry | 14 |
two different | 14 |
peritrophic matrix | 14 |
white matter | 14 |
five times | 14 |
animal experiments | 14 |
lps injury | 14 |
protein corona | 14 |
lung tissues | 14 |
tea extract | 14 |
infectious evs | 14 |
rsv challenge | 14 |
class ii | 14 |
antibody titer | 14 |
mhc class | 14 |
supplementary materials | 14 |
wako pure | 14 |
specific cd | 14 |
immunization groups | 14 |
polyacrylamide gel | 14 |
mesenchymal stem | 14 |
small intestine | 14 |
pure chemical | 14 |
therapeutic effect | 14 |
cells well | 14 |
sheep cells | 14 |
wide range | 14 |
target antigen | 14 |
genomic dna | 14 |
adcc activity | 14 |
reverse transcriptase | 13 |
treated ferrets | 13 |
culture supernatants | 13 |
staphylococcus aureus | 13 |
lymphocyte proliferation | 13 |
pvdf membrane | 13 |
toxoplasma gondii | 13 |
polyclonal antiserum | 13 |
infectious diseases | 13 |
serial dilutions | 13 |
transcription factors | 13 |
secretory lysosomes | 13 |
affinity selection | 13 |
epithelial cell | 13 |
stx holotoxin | 13 |
also found | 13 |
cellular immune | 13 |
apis mellifera | 13 |
cellular immunity | 13 |
single cell | 13 |
lung uptake | 13 |
gel electrophoresis | 13 |
fold change | 13 |
ige sensitization | 13 |
serially diluted | 13 |
life technologies | 13 |
human antibody | 13 |
cells transfected | 13 |
cells ml | 13 |
igy antibodies | 13 |
virus released | 13 |
pfu ml | 13 |
ige alone | 13 |
vivo imaging | 13 |
crude rubi | 13 |
oral administration | 13 |
acute inflammation | 13 |
humoral immunity | 13 |
mouse lungs | 13 |
may also | 13 |
mdck cells | 13 |
endogenous betaretroviruses | 13 |
dendritic cells | 13 |
individual phytoplankton | 13 |
fluorescent protein | 13 |
protective efficacy | 13 |
reverse transcription | 13 |
recent study | 13 |
sterile pbs | 13 |
monomeric ige | 13 |
quantified using | 12 |
flow cytometric | 12 |
treated cells | 12 |
per well | 12 |
iav infection | 12 |
viral infections | 12 |
medium containing | 12 |
inflammatory cells | 12 |
cell death | 12 |
error bars | 12 |
membrane protein | 12 |
first immunization | 12 |
mutant dpp | 12 |
group showed | 12 |
gene transfer | 12 |
tumor necrosis | 12 |
considered significant | 12 |
elisa plate | 12 |
binding protein | 12 |
viral proteins | 12 |
parasite burden | 12 |
secondary antibodies | 12 |
open reading | 12 |
data suggest | 12 |
th immunity | 12 |
previous study | 12 |
cell populations | 12 |
recombinant proteins | 12 |
necrosis factor | 12 |
graphpad prism | 12 |
real time | 12 |
dipeptidyl peptidase | 12 |
like particles | 12 |
mrna expression | 12 |
lung homogenate | 12 |
lung sections | 12 |
human serum | 12 |
equal volume | 12 |
significant decrease | 12 |
encephalitis virus | 12 |
wall proteins | 12 |
mice per | 12 |
binding domain | 12 |
cold pbs | 12 |
stem cells | 12 |
biosafety level | 12 |
coronavirus infection | 12 |
like receptor | 12 |
indirect elisas | 12 |
free protein | 12 |
adult mice | 12 |
rubisco large | 12 |
data analysis | 12 |
virus infections | 12 |
vaccine group | 11 |
reaction mixture | 11 |
blocking buffer | 11 |
cytokine expression | 11 |
vaccinia virus | 11 |
hibiscus sabdariffa | 11 |
initial dose | 11 |
human monoclonal | 11 |
phytoplankton cells | 11 |
mm tris | 11 |
imaging system | 11 |
nuclear export | 11 |
acidic ph | 11 |
pbs bsa | 11 |
ferulic acid | 11 |
extracellular vesicles | 11 |
old balb | 11 |
expression level | 11 |
genes involved | 11 |
yolk antibodies | 11 |
weaned mice | 11 |
clinical signs | 11 |
injection site | 11 |
recombinant swinepox | 11 |
luciferase activity | 11 |
way analysis | 11 |
cov infection | 11 |
reading frame | 11 |
antibody phage | 11 |
cellular membranes | 11 |
highly conserved | 11 |
pulmonary edema | 11 |
recombinant stx | 11 |
current protocols | 11 |
virus challenge | 11 |
thoracic suction | 11 |
three washes | 11 |
multiple sclerosis | 11 |
receptor tyrosine | 11 |
genes coding | 11 |
class i | 11 |
igf receptor | 11 |
virus production | 11 |
nk cells | 11 |
sandwich elisa | 11 |
factor receptor | 11 |
ppp group | 11 |
transport media | 11 |
distilled water | 11 |
closely related | 11 |
dependent cell | 11 |
bronchoalveolar lavage | 11 |
ibv spike | 11 |
protein assay | 11 |
bsl facility | 11 |
facs buffer | 11 |
recent studies | 11 |
pas staining | 11 |
sars patients | 11 |
rsv vaccine | 11 |
dna vaccination | 11 |
cytokine production | 11 |
cytokine levels | 11 |
per cell | 11 |
conjugated secondary | 11 |
scientificreports www | 11 |
lung inflammation | 10 |
intraperitoneally injected | 10 |
survival time | 10 |
excitation laser | 10 |
significant reduction | 10 |
igf group | 10 |
fluorescence microscopy | 10 |
main workbench | 10 |
blank control | 10 |
albumin binding | 10 |
control cells | 10 |
acid residues | 10 |
iv lps | 10 |
conjugated goat | 10 |
particle size | 10 |
vaccine development | 10 |
evs containing | 10 |
clc main | 10 |
reference genes | 10 |
recombinant siga | 10 |
group vii | 10 |
higher levels | 10 |
individual cells | 10 |
lysis buffer | 10 |
photon imaging | 10 |
caa siga | 10 |
cell response | 10 |
driven host | 10 |
ge healthcare | 10 |
length spike | 10 |
total protein | 10 |
ammonium sulfate | 10 |
infected sheep | 10 |
node cells | 10 |
several genes | 10 |
experimental conditions | 10 |
serial dilution | 10 |
pei anti | 10 |
viral antigens | 10 |
murine model | 10 |
inactivated vaccine | 10 |
primary antibody | 10 |
culture supernatant | 10 |
intratracheal administration | 10 |
bee health | 10 |
tcid ml | 10 |
endogenous retroviruses | 10 |
productively infect | 10 |
significantly increased | 10 |
influenza vaccines | 10 |
classification algorithm | 10 |
authors declare | 10 |
treated samples | 10 |
antibody solution | 10 |
structural proteins | 10 |
nucleotide sequence | 10 |
pei sirna | 10 |
mice immunised | 10 |
sm immunization | 10 |
naive mice | 10 |
public health | 10 |
ethylene glycol | 10 |
target protein | 10 |
th cells | 10 |
spike glycoprotein | 10 |
gastroenteritis coronavirus | 10 |
genbank accession | 10 |
whole inactivated | 10 |
infected ferrets | 10 |
tlr expression | 10 |
reactive mabs | 10 |
accession number | 10 |
bronchitis virus | 10 |
vero cells | 10 |
binding specificity | 10 |
critical role | 10 |
sybr green | 10 |
nanoparticle size | 10 |
signaling pathway | 10 |
measured using | 10 |
overall clinical | 10 |
pas airways | 10 |
three groups | 10 |
total dna | 10 |
virus type | 10 |
inactivated virus | 10 |
determined using | 10 |
mouse lung | 10 |
protein kinase | 10 |
growth factors | 10 |
cytometric analysis | 10 |
mediated cytotoxicity | 10 |
using two | 10 |
dpp polymorphisms | 10 |
monitored daily | 10 |
dpp wt | 10 |
immunized group | 10 |
universal influenza | 10 |
nm bafa | 10 |
th vector | 10 |
enveloped virus | 10 |
early stages | 10 |
dpp expression | 9 |
calf serum | 9 |
viral titers | 9 |
results indicated | 9 |
coronavirus spike | 9 |
campylobacter species | 9 |
specific anti | 9 |
use committee | 9 |
purified using | 9 |
statistical analyses | 9 |
time rt | 9 |
acid sequence | 9 |
recombinant antigens | 9 |
transmission electron | 9 |
viral challenge | 9 |
time quantitative | 9 |
viral titer | 9 |
endocytic pathways | 9 |
vaccine candidate | 9 |
total cell | 9 |
ml per | 9 |
entry route | 9 |
capture elisa | 9 |
lung edema | 9 |
antibacterial activity | 9 |
nk cell | 9 |
lps administration | 9 |
crude rmers | 9 |
upper respiratory | 9 |
blood cells | 9 |
west nile | 9 |
cell monolayers | 9 |
purified rubi | 9 |
innate immunity | 9 |
female mice | 9 |
gal specificity | 9 |
parasite load | 9 |
cells via | 9 |
transfected cells | 9 |
values obtained | 9 |
thermo scientific | 9 |
expression vectors | 9 |
young children | 9 |
tyrosine kinase | 9 |
supramolecular organization | 9 |
ha titer | 9 |
sample buffer | 9 |
like protein | 9 |
light scattering | 9 |
results demonstrated | 9 |
gene therapy | 9 |
viral pathogens | 9 |
bl mice | 9 |
od nm | 9 |
basic protocol | 9 |
nervous system | 9 |
pure product | 9 |
obtained using | 9 |
mm edta | 9 |
respiratory disease | 9 |
protein nanoparticles | 9 |
response elicited | 9 |
san diego | 9 |
cytokine responses | 9 |
protein bands | 9 |
bare liposomes | 9 |
ml microtubes | 9 |
cell proliferation | 9 |
rsv pref | 9 |
cell infiltration | 9 |
antiviral drugs | 9 |
synthetic peptides | 9 |
rna extraction | 9 |
cover glass | 9 |
eap treatment | 9 |
vaccine constructs | 9 |
japan virus | 9 |
creative commons | 9 |
virus vaccine | 9 |
ebov gp | 9 |
experimentally infected | 9 |
elution buffer | 9 |
pathogenic avian | 9 |
gold nanoparticles | 9 |
virus disease | 9 |
adaptive immunity | 9 |
oral immunization | 9 |
animal model | 9 |
apical side | 9 |
oral gavage | 9 |
outer capsid | 9 |
human iga | 9 |
blood vessels | 9 |
herbal medicines | 9 |
lamina propria | 9 |
ad libitum | 9 |
dpp residues | 9 |
molecular probes | 9 |
containing fcs | 9 |
chronic inflammation | 9 |
viral entry | 9 |
statistical difference | 9 |
weekly intervals | 9 |
analysis using | 9 |
positive binders | 9 |
kindly provided | 9 |
inflammatory injury | 9 |
signal transduction | 9 |
mammalian cells | 9 |
likely due | 9 |
mm dynasore | 9 |
antibody levels | 9 |
infected patients | 9 |
significant increases | 9 |
lung pathology | 9 |
rat model | 9 |
assay kit | 9 |
washed times | 9 |
protein content | 9 |
rabies dna | 9 |
first step | 8 |
insect cells | 8 |
linear discriminant | 8 |
secretory iga | 8 |
week old | 8 |
protein nps | 8 |
surface tension | 8 |
expression patterns | 8 |
nanoparticle tracking | 8 |
stomatitis virus | 8 |
significant increase | 8 |
may provide | 8 |
immunised mothers | 8 |
left lungs | 8 |
iu ml | 8 |
rh strain | 8 |
specific binding | 8 |
protein sequence | 8 |
high concentration | 8 |
cell responses | 8 |
tyrosine kinases | 8 |
deficient mice | 8 |
animals positive | 8 |
vesicular stomatitis | 8 |
infection exclusion | 8 |
consensus sequence | 8 |
mab mm | 8 |
deer mice | 8 |
viral protein | 8 |
amino acids | 8 |
bound phages | 8 |
entry routes | 8 |
dependent manner | 8 |
rna viruses | 8 |
preliminary experiments | 8 |
previous work | 8 |
casei vaccine | 8 |
intravital microscopy | 8 |
fusion protein | 8 |
chicken eggs | 8 |
phage titres | 8 |
ng ml | 8 |
nucleic acid | 8 |
confocal laser | 8 |
fluorescence intensity | 8 |
intracellular signaling | 8 |
structural protein | 8 |
fetal calf | 8 |
colony collapse | 8 |
mucosal delivery | 8 |
kg body | 8 |
cryptosporidium spp | 8 |
collapse disorder | 8 |
pulmonary microcirculation | 8 |
may contribute | 8 |
protease inhibitor | 8 |
page blue | 8 |
plaque assay | 8 |
nile virus | 8 |
molecular mechanisms | 8 |
solution containing | 8 |
positive controls | 8 |
proinflammatory cytokines | 8 |
data obtained | 8 |
significantly reduced | 8 |
kappa light | 8 |
also showed | 8 |
clinical scores | 8 |
initial immunisation | 8 |
cells may | 8 |
pulmonary marginated | 8 |
frugiperda caterpillars | 8 |
two colonies | 8 |
producing cd | 8 |
animal models | 8 |
th type | 8 |
laser scanning | 8 |
lower respiratory | 8 |
disease control | 8 |
protein vp | 8 |
reduced mers | 8 |
ml penicillin | 8 |
igf expression | 8 |
yolk immunoglobulin | 8 |
relatively high | 8 |
infection date | 8 |
scale bar | 8 |
gondii rh | 8 |
receiving pbs | 8 |
membrane fusion | 8 |
rubisco activity | 8 |
conducted using | 8 |
wash buffer | 8 |
fold serial | 8 |
cell viability | 8 |
optical density | 8 |
tract infections | 8 |
recombination event | 8 |
female balb | 8 |
supplemental figures | 8 |
allantoic fluid | 8 |
protein level | 8 |
severe pneumonia | 8 |
hinokitiol administration | 8 |
receptor binding | 8 |
much lower | 8 |
signal sequences | 8 |
standard deviation | 8 |
significantly different | 8 |
rabbit antiserum | 8 |
separate experiments | 8 |
type diabetes | 8 |
corona formation | 8 |
viral genome | 8 |
gammaretroviral env | 8 |
glycosylated proteins | 8 |
following pr | 8 |
tracking analysis | 8 |
buffered formalin | 8 |
united states | 8 |
lethal dose | 8 |
primary immunization | 8 |
extracted using | 8 |
inflammatory cell | 8 |
coated wells | 8 |
also evaluated | 8 |
fibrotic evolution | 8 |
endosomal pathway | 8 |
given ip | 8 |
lactobacillus casei | 8 |
binding capacity | 8 |
following rsv | 8 |
cell membrane | 8 |
nebulized lps | 8 |
experimental groups | 8 |
spodoptera frugiperda | 8 |
array assay | 8 |
ml pbs | 8 |
widely used | 8 |
virus expressing | 8 |
sudlow i | 8 |
previous reports | 8 |
endogenous retrovirus | 8 |
results obtained | 8 |
cd antibody | 8 |
uremic syndrome | 8 |
supplementary material | 8 |
orally administered | 8 |
rubisco concentration | 8 |
sensitization alone | 8 |
large number | 8 |
protein levels | 8 |
graphpad software | 8 |
jugular vein | 8 |
mm nacl | 8 |
electron microscope | 8 |
ml streptomycin | 8 |
early diagnosis | 8 |
ind iav | 8 |
human endogenous | 8 |
airway epithelial | 8 |
il sirna | 8 |
japan strain | 8 |
protein flid | 7 |
infected caterpillars | 7 |
safety profile | 7 |
reactive siga | 7 |
differentiated airway | 7 |
delta inulin | 7 |
kda cutoff | 7 |
pbs ii | 7 |
conventional eia | 7 |
np uptake | 7 |
polyclonal antibodies | 7 |
using graphpad | 7 |
capping protein | 7 |
using real | 7 |
tissue samples | 7 |
calculated accordingly | 7 |
human respiratory | 7 |
animal ethics | 7 |
mice received | 7 |
commercially available | 7 |
immunised mice | 7 |
specific monoclonal | 7 |
nucleocapsid protein | 7 |
antigenic sites | 7 |
major histocompatibility | 7 |
mediated endocytosis | 7 |
bronchial epithelial | 7 |
future studies | 7 |
capsid antibody | 7 |
virus hemagglutinin | 7 |
immune function | 7 |
pathological changes | 7 |
clinical use | 7 |
treatment effects | 7 |
training set | 7 |
detection limit | 7 |
master mix | 7 |
three different | 7 |
rna export | 7 |
total number | 7 |
mammary tumor | 7 |
per igg | 7 |
gapdh sirna | 7 |
chinese herb | 7 |
btv particles | 7 |
confocal microscope | 7 |
humoral immune | 7 |
nitrocellulose membrane | 7 |
infection model | 7 |
adcc antibodies | 7 |
sirna delivery | 7 |
cell suspension | 7 |
four groups | 7 |
spleen cells | 7 |
mucosal immunity | 7 |
detecting antibody | 7 |
bd pharmingen | 7 |
pulmonary pathology | 7 |
pmol photons | 7 |
dpp mutants | 7 |
natural killer | 7 |
human milk | 7 |
fluorescent dyes | 7 |
mouse mammary | 7 |
acid substitution | 7 |
overnight incubation | 7 |
purified evs | 7 |
automated plate | 7 |
study design | 7 |
containing virus | 7 |
induced demyelination | 7 |
see note | 7 |
injected bees | 7 |
decision tree | 7 |
ct scan | 7 |
described methods | 7 |
human trachea | 7 |
jackson immunoresearch | 7 |
signal intensity | 7 |
hemolytic uremic | 7 |
inactivating agent | 7 |
following parameters | 7 |
weeks old | 7 |
faecal samples | 7 |
pulmonary neutrophils | 7 |
pneumonia model | 7 |
prism software | 7 |
following infection | 7 |
virus strains | 7 |
naturally infected | 7 |
neutrophil recruitment | 7 |
alveolar epithelial | 7 |
mouse anti | 7 |
liposome uptake | 7 |
animal studies | 7 |
immune sera | 7 |
ct images | 7 |
serum antibody | 7 |
data show | 7 |
stranded rna | 7 |
binding proteins | 7 |
evs secreted | 7 |
cytokine storm | 7 |
investigate whether | 7 |
three days | 7 |
nanoparticle uptake | 7 |
tumor virus | 7 |
sin nombre | 7 |
protein synthesis | 7 |
associated virus | 7 |
nasal washes | 7 |
actin dynamics | 7 |
antibody titres | 7 |
phage preincubation | 7 |
cd cells | 7 |
inactivated pr | 7 |
polystyrene nps | 7 |
mm ca | 7 |
clinical samples | 7 |
go terms | 7 |
cell lysis | 7 |
washed five | 7 |
vlp entry | 7 |
dot blot | 7 |
copy number | 7 |
carl zeiss | 7 |
od values | 7 |
absolute quantification | 7 |
treatment group | 7 |
approved drugs | 7 |
statistical analysis | 7 |
secretory component | 7 |
per ml | 7 |
multichannel pipettor | 7 |
ethics committee | 7 |
affinity purification | 7 |
genus betaretrovirus | 7 |
denaturing conditions | 7 |
protein fraction | 7 |
plate washer | 7 |
neutralizing activity | 7 |
hong kong | 7 |
human disease | 7 |
dpi survived | 7 |
three mice | 7 |
blocking solution | 7 |
mrna levels | 7 |
expression pattern | 7 |
developing countries | 7 |
dromedary camels | 7 |
bisphosphate carboxylase | 7 |
institutional animal | 7 |
mortality rate | 7 |
target antigens | 7 |
cells per | 7 |
whole blood | 7 |
fold increase | 7 |
stop codon | 7 |
breast cancer | 7 |
skimmed milk | 7 |
study showed | 7 |
slightly higher | 7 |
proteins expressed | 7 |
one sample | 7 |
using recombinant | 7 |
immune recognition | 7 |
expression analysis | 7 |
basal secretions | 7 |
nonstructural protein | 7 |
acute paralysis | 7 |
inflammatory mediators | 7 |
primary antibodies | 7 |
inflammatory effects | 7 |
photosynthetic rates | 7 |
way anova | 7 |
immunofluorescence assay | 7 |
many studies | 7 |
primary production | 7 |
blood coagulation | 7 |
host species | 7 |
randomly divided | 7 |
maximal photosynthetic | 7 |
dpp surface | 7 |
differential expression | 7 |
cellular cytotoxicity | 7 |
size exclusion | 7 |
franklin lakes | 7 |
type cytokine | 7 |
six mice | 7 |
associated coronavirus | 7 |
transferred onto | 7 |
provide protection | 7 |
th cd | 7 |
lpeg anti | 7 |
immune enhancement | 7 |
btv infection | 7 |
survival rates | 7 |
protective effects | 7 |
type immune | 7 |
considered statistically | 7 |
fixed cells | 7 |
cells following | 7 |
competing interests | 6 |
full speed | 6 |
crosslinked albumin | 6 |
lung imaging | 6 |
even though | 6 |
sn antibody | 6 |
four hours | 6 |
mg per | 6 |
nanoparticles based | 6 |
capsid protein | 6 |
negative selection | 6 |
page gel | 6 |
via flow | 6 |
th immune | 6 |
anti vp | 6 |
virus preparations | 6 |
protein interactions | 6 |
analysis revealed | 6 |
five days | 6 |
ha activity | 6 |
mounting fluid | 6 |
culture plate | 6 |
probe displacement | 6 |
serum neutralization | 6 |
igf plays | 6 |
thin sections | 6 |
acquired pneumonia | 6 |
demyelinating strain | 6 |
following lps | 6 |
acute phase | 6 |
tissue sections | 6 |
herpes simplex | 6 |
infective dose | 6 |
microtiter plates | 6 |
large amounts | 6 |
complement activation | 6 |
liquid interface | 6 |
sars samples | 6 |
purified antiserum | 6 |
jcdv infection | 6 |
increasing concentrations | 6 |
genetic level | 6 |
virus receptor | 6 |
infected cattle | 6 |
antiviral candidates | 6 |
mouse models | 6 |
becton dickinson | 6 |
sodium new | 6 |
parasite loads | 6 |
histocompatibility complex | 6 |
infected lungs | 6 |
infectious virus | 6 |
egg yolks | 6 |
ccg siga | 6 |
results presented | 6 |
stock solution | 6 |
quantitative rt | 6 |
bacteria motility | 6 |
cells grown | 6 |
goblet cells | 6 |
infection induces | 6 |
laying hens | 6 |
determine whether | 6 |
heavy chain | 6 |
biopanning simulation | 6 |
airway cells | 6 |
prepared using | 6 |
blast go | 6 |
parvum infection | 6 |
lysine trna | 6 |
peripheral blood | 6 |
type i | 6 |
culture system | 6 |
lysosomal markers | 6 |
physicochemical properties | 6 |
using one | 6 |
th cell | 6 |
binding buffer | 6 |
corresponding author | 6 |
human ige | 6 |
three genes | 6 |
passive transfer | 6 |
murine microbiota | 6 |
liquid nitrogen | 6 |
human lung | 6 |
tree classification | 6 |
may represent | 6 |
enteric pathogens | 6 |
nanoparticle solutions | 6 |
nitrocellulose membranes | 6 |
acidic hibiscus | 6 |
santa cruz | 6 |
rna genome | 6 |
exposure treatment | 6 |
sequence gb | 6 |
control animals | 6 |
human albumin | 6 |
unag fluorescence | 6 |
igy showed | 6 |
hydroxychloroquine sulfate | 6 |
days prior | 6 |
teer values | 6 |
strain nu | 6 |
pro vibrating | 6 |
infect airway | 6 |
sa peptides | 6 |
histological analysis | 6 |
studies demonstrated | 6 |
immunization produced | 6 |
th responses | 6 |
mock group | 6 |
sialic acids | 6 |
previously published | 6 |
inflammatory cytokine | 6 |
entry via | 6 |
ko phage | 6 |
adult flukes | 6 |
simultaneous detection | 6 |
various concentrations | 6 |
directly infect | 6 |
different cell | 6 |
adcc epitopes | 6 |
fecal samples | 6 |
bat genomes | 6 |
virus infected | 6 |
nebulised pei | 6 |
final volume | 6 |
human fascioliasis | 6 |
two distinct | 6 |
considered positive | 6 |
quantitative analysis | 6 |
lung collapse | 6 |
jejuni infection | 6 |
first plate | 6 |
protein solutions | 6 |
acid sequences | 6 |
bca protein | 6 |
mice born | 6 |
supplementary figures | 6 |
alecto transcriptome | 6 |
kinase inhibitors | 6 |
avian infectious | 6 |
autoimmune diseases | 6 |
cell population | 6 |
treated controls | 6 |
standard deviations | 6 |
vaccine may | 6 |
well known | 6 |
existing neutralizing | 6 |
akt signaling | 6 |
significantly enhanced | 6 |
systemic administration | 6 |
nps based | 6 |
pneumoniae strain | 6 |
crystal violet | 6 |
ct data | 6 |
groups tested | 6 |
novel anti | 6 |
reporter mouse | 6 |
nebulised sirna | 6 |
immunization elicited | 6 |
facs diva | 6 |
lethal influenza | 6 |
thank dr | 6 |
wiv vaccine | 6 |
herb groups | 6 |
growth irradiance | 6 |
multiple virus | 6 |
od signals | 6 |
igg antibody | 6 |
investigated whether | 6 |
jcdv capsids | 6 |
hcq sulfate | 6 |
laboratory animals | 6 |
hydrophobic interactions | 6 |
pbs solution | 6 |
native virions | 6 |
synthetic nanoparticles | 6 |
intranasal administration | 6 |
high degree | 6 |
nombre virus | 6 |
passive immunotherapy | 6 |
chinese traditional | 6 |
mice receiving | 6 |
viral infectivity | 6 |
significantly less | 6 |
five encephalitis | 6 |
balanced adjuvants | 6 |
sodium dodecyl | 6 |
like proteins | 6 |
wild type | 6 |
bacterial load | 6 |
low levels | 6 |
viral transport | 6 |
therapeutic potential | 6 |
beneficial effects | 6 |
word size | 6 |
peritrophic membrane | 6 |
background signal | 6 |
cardiogenic pulmonary | 6 |
spinach rubisco | 6 |
sn titers | 6 |
average weight | 6 |
total volume | 6 |
dependent cellular | 6 |
specific primers | 6 |
elisas based | 6 |
infected groups | 6 |
tissue repair | 6 |
using flow | 6 |
ph environment | 6 |
specific adcc | 6 |
hgn siga | 6 |
three rfhpcls | 6 |
treated rats | 6 |
traditional chinese | 6 |
used instead | 6 |
incomplete adjuvant | 6 |
bone marrow | 6 |
responses induced | 6 |
immunized groups | 6 |
assay using | 6 |
inhibitory activity | 6 |
restriction sites | 6 |
relatively low | 6 |
pandemic influenza | 6 |
cov replication | 6 |
env sequences | 6 |
antigen display | 6 |
phage library | 6 |
studies showed | 6 |
dietary intake | 6 |
infected mouse | 6 |
iapv infection | 6 |
rabbit antisera | 6 |
complete adjuvant | 6 |
antigen extracts | 6 |
connecting tube | 6 |
sequence specificity | 6 |
wt mice | 6 |
water ad | 6 |
virus strain | 6 |
dna polymerase | 6 |
specific iga | 6 |
crosslinked protein | 6 |
central nervous | 6 |
essential medium | 6 |
cell adhesion | 6 |
affinity chromatography | 6 |
iav particles | 6 |
exclusion chromatography | 6 |
normal bvs | 6 |
lung damage | 6 |
make aliquots | 6 |
skim milk | 6 |
pcr assay | 6 |
five mice | 6 |
vaccine formulations | 6 |
virus vaccines | 6 |
growth medium | 6 |
place plates | 6 |
na co | 6 |
antigen binding | 6 |
acidic protein | 6 |
multiple comparison | 6 |
nah po | 6 |
ml min | 6 |
ibv virions | 6 |
diva software | 6 |
log tcid | 6 |
pbs immunized | 6 |
sequence analysis | 6 |
ct imaging | 6 |
early time | 6 |
ribosomal biogenesis | 6 |
ramp rate | 6 |
pulmonary delivery | 6 |
linked sialic | 6 |
tyrosine phosphorylation | 6 |
human igg | 6 |
antibiotic resistance | 6 |
phage elisa | 6 |
cell pellet | 6 |
virulence factors | 6 |
expression data | 6 |
toxicity study | 6 |
high titers | 6 |
enhanced green | 6 |
first line | 6 |
elisa kit | 6 |
excitation microscopy | 6 |
leukemia virus | 6 |
iav replication | 6 |
two groups | 6 |
serum levels | 6 |
bal samples | 6 |
primary human | 6 |
specific binders | 6 |
image analysis | 6 |
four times | 6 |
low complexity | 6 |
human mesenchymal | 6 |
tissue dye | 6 |
independent anti | 6 |
induced specific | 6 |
containing pbs | 6 |
scfv library | 6 |
evaluated using | 6 |
discriminant analysis | 6 |
dna constructs | 6 |
virus neutralization | 6 |
phage particles | 6 |
using anti | 6 |
sheep sera | 6 |
viral envelope | 6 |
higher level | 6 |
expression profiles | 6 |
background fluorescence | 6 |
diverse range | 6 |
different experimental | 6 |
well tolerated | 5 |
host immune | 5 |
cd signal | 5 |
clinical features | 5 |
centrifugal filter | 5 |
gaussia luciferase | 5 |
albumin np | 5 |
fever virus | 5 |
bars indicate | 5 |
iapv injection | 5 |
clinical trial | 5 |
pm proteins | 5 |
cells infiltration | 5 |
greater th | 5 |
droplet size | 5 |
intestinal tract | 5 |
bicarbonate buffer | 5 |
data presented | 5 |
siga format | 5 |
light microscopy | 5 |
fluorescence signal | 5 |
reading frames | 5 |
specific inhibitor | 5 |
japanese encephalitis | 5 |
phage towards | 5 |
wallis test | 5 |
macropinosome formation | 5 |
peg sirna | 5 |
weak low | 5 |
productive infection | 5 |
polarised calu | 5 |
starting sample | 5 |
least two | 5 |
within days | 5 |
response following | 5 |
goat serum | 5 |
mers coronavirus | 5 |
containing milk | 5 |
control sera | 5 |
background phages | 5 |
rabies glycoprotein | 5 |
fc binding | 5 |
jcdv binding | 5 |
significant decreases | 5 |
head region | 5 |
co buffer | 5 |
hiv infection | 5 |
elisa kits | 5 |
dry lung | 5 |
canine kidney | 5 |
increased expression | 5 |
breast milk | 5 |
chicken blood | 5 |
antigenic determinants | 5 |
protein database | 5 |
first time | 5 |
similar levels | 5 |
several viruses | 5 |
randomly selected | 5 |
public databases | 5 |
scanning microscope | 5 |
fluorescence microscope | 5 |
eagle medium | 5 |
phase endocytosis | 5 |
activated microglia | 5 |
inguinal lymph | 5 |
well microtiter | 5 |
junonia coenia | 5 |
neutralization titer | 5 |
well tissue | 5 |
sag gene | 5 |
repeated administration | 5 |
beckman coulter | 5 |
centrifugal filters | 5 |
peer review | 5 |
carrier protein | 5 |
stem cell | 5 |
microscopy images | 5 |
cfu mouse | 5 |
fold difference | 5 |
enhanced pulmonary | 5 |
dilution plate | 5 |
uranyl acetate | 5 |
intestinal epithelial | 5 |
intratracheally infected | 5 |
chitin synthesis | 5 |
bolus delivery | 5 |
min followed | 5 |
positive results | 5 |
immunized hens | 5 |
coli strain | 5 |
high level | 5 |
sphingosine kinase | 5 |
received ml | 5 |
may result | 5 |
new houttuyfonate | 5 |
filtered using | 5 |
saturated rates | 5 |
cellular responses | 5 |
animal health | 5 |
viral proliferation | 5 |
veg caterpillar | 5 |
chain reaction | 5 |
indirect immunofluorescence | 5 |
energy readings | 5 |
serum neutralizing | 5 |
cellular receptor | 5 |
pei pei | 5 |
sirna transfection | 5 |
sheep retrovirus | 5 |
human influenza | 5 |
response induced | 5 |
balanced adjuvant | 5 |
mouse sera | 5 |
virus isolates | 5 |
species assemblages | 5 |
od value | 5 |
days old | 5 |
protein purification | 5 |
ferritin nanocages | 5 |
plasminogen activator | 5 |
rubisco concentrations | 5 |
rsv disease | 5 |
administered flid | 5 |
inactivated purified | 5 |
see supplementary | 5 |
applied biosystems | 5 |
pseudomonas aeruginosa | 5 |
following fc | 5 |
also known | 5 |
rsv immunization | 5 |
ultra centrifugal | 5 |
hepatica cathepsin | 5 |
ibav infection | 5 |
botanical polysaccharides | 5 |
key role | 5 |
cell growth | 5 |
transmembrane protein | 5 |
dna plasmid | 5 |
blinded test | 5 |
mass spectrometry | 5 |
alveolar walls | 5 |
ii sites | 5 |
similar results | 5 |
also examined | 5 |
neural network | 5 |
virus release | 5 |
neutrophil elastase | 5 |
cord blood | 5 |
see section | 5 |
per year | 5 |
administered via | 5 |
least three | 5 |
chicken igy | 5 |
dbco per | 5 |
respiratory infections | 5 |
shiga toxins | 5 |
endoplasmic reticulum | 5 |
newborn mice | 5 |
lpeg nt | 5 |
mediated immune | 5 |
cell receptor | 5 |
drug administration | 5 |
viral inoculation | 5 |
ha stem | 5 |
coronavirus associated | 5 |
lung weight | 5 |
immune protection | 5 |
water bath | 5 |
evolutionary history | 5 |
data represent | 5 |
varroa destructor | 5 |
also increased | 5 |
protects mice | 5 |
cs values | 5 |
intestinal inflammation | 5 |
antimicrobial resistance | 5 |
experimental infection | 5 |
immunized piglets | 5 |
endothelial cells | 5 |
monoclonal elisa | 5 |
commons license | 5 |
lesser extent | 5 |
seven days | 5 |
viral pathogenesis | 5 |
long time | 5 |
intranasally inoculated | 5 |
coding sequence | 5 |
untreated group | 5 |
actin cytoskeleton | 5 |
different species | 5 |
secretory immunoglobulin | 5 |
freshly prepared | 5 |
cell debris | 5 |
global health | 5 |
deionised water | 5 |
capsid proteins | 5 |
tight junctions | 5 |
different types | 5 |
pas cells | 5 |
using either | 5 |
rsa infection | 5 |
specific egg | 5 |
draining lymph | 5 |
azide liposomes | 5 |
containing monomers | 5 |
acidic pbs | 5 |
experimental models | 5 |
pentraxin ptx | 5 |
supplementary information | 5 |
per sample | 5 |
gentle rotation | 5 |
also reported | 5 |
nitric oxide | 5 |
surface energies | 5 |
vaccine groups | 5 |
using pbs | 5 |
copro elisa | 5 |
protein formulation | 5 |
current infection | 5 |
ncbi non | 5 |
laboratory conditions | 5 |
export pathway | 5 |
red blood | 5 |
lipid membrane | 5 |
firefly luciferase | 5 |
least ml | 5 |
footpad lps | 5 |
stimulation index | 5 |
protect mice | 5 |
cellular functions | 5 |
grey bars | 5 |
major role | 5 |
several times | 5 |
dependent mechanism | 5 |
seasonal influenza | 5 |
virus proteins | 5 |
nm gold | 5 |
reverse primer | 5 |
periodic acid | 5 |
imaging analysis | 5 |
start methionine | 5 |
transwell insert | 5 |
adoptive transfer | 5 |
transcription factor | 5 |
hain conformation | 5 |
phosphonic acid | 5 |
intestinal content | 5 |
cell cultures | 5 |
israeli acute | 5 |
passive immunization | 5 |
amicon ultra | 5 |
polymorphic residues | 5 |
intravital imaging | 5 |
mucosal immunisation | 5 |
neutralization assay | 5 |
porcine mucins | 5 |
epithelial surface | 5 |
integrated density | 5 |
sf cells | 5 |
equine arteritis | 5 |
secondary structure | 5 |
virus particle | 5 |
nasal turbinate | 5 |
membrane ruffling | 5 |
six times | 5 |
candida albicans | 5 |
lung index | 5 |
live attenuated | 5 |
detection system | 5 |
igg liposome | 5 |
nahco na | 5 |
four injections | 5 |
gap costs | 5 |
significant dose | 5 |
immunomodulatory activities | 5 |
conventional elisa | 5 |
pbs iic | 5 |
mock infected | 5 |
conjugated antibodies | 5 |
mediated acute | 5 |
additional orfs | 5 |
recombinant peptides | 5 |
also upregulated | 5 |
green fluorescence | 5 |
per dose | 5 |
reduced pressure | 5 |
antiviral activities | 5 |
virus binding | 5 |
antiviral effects | 5 |
protease inhibitors | 5 |
minutes prior | 5 |
urea buffer | 5 |
long pentraxin | 5 |
control samples | 5 |
chinese medicine | 5 |
performed according | 5 |
coenia densovirus | 5 |
demyelinating plaque | 5 |
elisa using | 5 |
gel filtration | 5 |
alum immunized | 5 |
humoral response | 5 |
lsr ii | 5 |
forming units | 5 |
ten mice | 5 |
healthy donors | 5 |
vivo behavior | 5 |
since integration | 5 |
vivo lung | 5 |
experimental animal | 5 |
enhanced respiratory | 5 |
cystic fibrosis | 5 |
increased inflammation | 5 |
tgev challenge | 5 |
stage impinger | 5 |
highly sensitive | 5 |
causative agent | 5 |
nanoparticles demonstrated | 5 |
total igy | 5 |
calcium signals | 5 |
independent activity | 5 |
one side | 5 |
puerto rico | 5 |
reverse transcytosis | 5 |
inflammatory activity | 5 |
antigen presentation | 5 |
neutrophil tropism | 5 |
one hour | 5 |
induced lung | 5 |
may play | 5 |
ii flow | 5 |
antibody binding | 5 |
flame sealed | 5 |
ml hinokitiol | 5 |
redundant protein | 5 |
endocytic pathway | 5 |
stabilized pref | 5 |
nhs ester | 5 |
major cause | 5 |
pen strep | 5 |
inclusion bodies | 5 |
vaccine candidates | 5 |
reducing conditions | 5 |
parvum oocysts | 5 |
predicted using | 5 |
single dose | 5 |
old female | 5 |
gamma counter | 5 |
receptor specificity | 5 |
immunofluorescence staining | 5 |
inflammatory reaction | 5 |
zen software | 5 |
pcr system | 5 |
phylogenetic analyses | 5 |
type mice | 5 |
arteritis virus | 5 |
last immunization | 5 |
rsv replication | 5 |
scanning microscopy | 5 |
pbs using | 5 |
highest dilution | 5 |
virus titer | 5 |
infected microglia | 5 |
modified eagle | 5 |
antiserum production | 5 |
cytometry data | 5 |
capture antibodies | 5 |
per gram | 5 |
hours post | 5 |
cytoskeleton remodeling | 5 |
acid changes | 5 |
quantitative real | 5 |
positive serum | 5 |
also shown | 5 |
lesion score | 5 |
densovirus infection | 5 |
polymerase chain | 5 |
binding site | 5 |
dna vectors | 5 |
analysis software | 5 |
rna virus | 5 |
protein domains | 5 |
copies per | 5 |
silver tablet | 5 |
purified equine | 5 |
encephalitis viruses | 5 |
infectious disease | 5 |
transfected bhk | 5 |
retroviral genes | 5 |
care unit | 5 |
viral inactivation | 5 |
per day | 5 |
host defense | 5 |
output rate | 5 |
ebov disease | 5 |
co incubator | 5 |
cell pellets | 5 |
wound healing | 5 |
chronic inflammatory | 5 |
cell stimulation | 5 |
pr viral | 5 |
cd cd | 5 |
whole cell | 5 |
different groups | 5 |
pbs complementary | 5 |
enhanced inflammation | 5 |
via oral | 5 |
cell imaging | 5 |
sodium azide | 5 |
membrane protrusions | 5 |
early infection | 5 |
maternal antibodies | 5 |
spike gene | 5 |
towards rubi | 5 |
splenic lymphocytes | 5 |
cells incubated | 5 |
biological activity | 5 |
opd solution | 5 |
two human | 5 |
lymphoid cells | 5 |
previously shown | 5 |
specific inhibitors | 5 |
infrared laser | 5 |
purified sars | 5 |
enterohemorrhagic escherichia | 5 |
fold dilutions | 5 |
primer binding | 5 |
single oral | 5 |
mice following | 5 |
active site | 5 |
vector vaccine | 5 |
digital gene | 5 |
rna copy | 5 |
respiratory epithelium | 5 |
mouse pneumonia | 5 |
single amino | 5 |
crystal structure | 5 |
may affect | 5 |
differential cell | 5 |
independent experiment | 5 |
fold molar | 5 |
laser path | 5 |
ph treatment | 5 |
simplex virus | 5 |
purified virus | 5 |
intensive care | 5 |
pbs via | 5 |
different times | 5 |
complexity filtered | 5 |
increased il | 5 |
protective immune | 5 |
ko phages | 5 |
serological assays | 5 |
glial cells | 5 |
vivo two | 5 |
mediated inflammation | 5 |
viral clearance | 5 |
column chromatography | 5 |
antibody libraries | 5 |
iga proteases | 5 |
groups treated | 5 |
signaling cascades | 5 |
experimental data | 5 |
protein sequences | 5 |
electrostatic interactions | 4 |
five rounds | 4 |
primer set | 4 |
albumin binders | 4 |
blosum matrix | 4 |
acute pulmonary | 4 |
antibody development | 4 |
veterinary medicine | 4 |
elisa test | 4 |
group compared | 4 |
fusion proteins | 4 |
headless ha | 4 |
single injection | 4 |
flash column | 4 |
strain wsn | 4 |
peptidase iv | 4 |
hi titer | 4 |
high cost | 4 |
inactivated rsv | 4 |
mock treatment | 4 |
weight change | 4 |
recombinant procathepsin | 4 |
myelin sheath | 4 |
pneumococcal dna | 4 |
min incubation | 4 |
studies will | 4 |
igg levels | 4 |
different host | 4 |
albumin nanoparticles | 4 |
data collection | 4 |
exclusion mechanism | 4 |
human neutrophils | 4 |
group exhibited | 4 |
high affinity | 4 |
important roles | 4 |
live imaging | 4 |
live cell | 4 |
antiinfluenza agents | 4 |
eupatorium adenophorum | 4 |
per plate | 4 |
dairy herds | 4 |
pharmacia biotech | 4 |
therapeutic effects | 4 |
passively immunised | 4 |
several studies | 4 |
type culture | 4 |
antiviral effect | 4 |
pbs groups | 4 |
chain scfv | 4 |
biodistribution studies | 4 |
bovine colostrums | 4 |
immune activity | 4 |
ferret infection | 4 |
protection conferred | 4 |
mouse anesthesia | 4 |
ciliated cells | 4 |
parasite antibodies | 4 |
transfection efficiency | 4 |
host range | 4 |
antibodies produced | 4 |
severe inflammation | 4 |
highly variable | 4 |
hinge region | 4 |
antibody targeting | 4 |
per egg | 4 |
healthy control | 4 |
small molecule | 4 |
sodium acetate | 4 |
pbs injection | 4 |
tgev spike | 4 |
hot plate | 4 |
delivery systems | 4 |
coronavirus vaccine | 4 |
dna encoding | 4 |
interacting proteins | 4 |
kg hinokitiol | 4 |
frequently associated | 4 |
enhanced chemiluminescence | 4 |
epithelial damage | 4 |
dmem containing | 4 |
following influenza | 4 |
may indicate | 4 |
binding studies | 4 |
biodistribution data | 4 |
pbs ph | 4 |
mm hepes | 4 |
ebov challenge | 4 |
istituto superiore | 4 |
hydrophobic domains | 4 |
icr mice | 4 |
fcs express | 4 |
binding sites | 4 |
therapeutic applications | 4 |
urgently needed | 4 |
study demonstrates | 4 |
fluorescein isothiocyanate | 4 |
panel represents | 4 |
tap water | 4 |
yolk igy | 4 |
original volume | 4 |
compared using | 4 |
blocking agent | 4 |
mcg ml | 4 |
also revealed | 4 |
antigenic site | 4 |
mfi value | 4 |
tracheal catheter | 4 |
exceed hr | 4 |
otherwise stated | 4 |
stimulated mast | 4 |
supplementary data | 4 |
containing fbs | 4 |
associated membrane | 4 |
presenting cells | 4 |
purified pr | 4 |
two hours | 4 |
receptor dpp | 4 |
raw data | 4 |
hoc test | 4 |
showed significant | 4 |
env genes | 4 |
one hundred | 4 |
recombinant viruses | 4 |
cytokine genes | 4 |
secondary antiserum | 4 |
amersham pharmacia | 4 |
protective role | 4 |
viral cultures | 4 |
peg precipitation | 4 |
ion current | 4 |
laser beam | 4 |
biomedical applications | 4 |
ionization time | 4 |
quantify rubisco | 4 |
day following | 4 |
probiotic bacteria | 4 |
gene products | 4 |
lps stimulation | 4 |
studies may | 4 |
evs infected | 4 |
first eigenvector | 4 |
calcium release | 4 |
using standard | 4 |
antigenic drift | 4 |
antigen preparations | 4 |
viral transmission | 4 |
filter units | 4 |
using phage | 4 |
internal stores | 4 |
cd spectra | 4 |
image registration | 4 |
including human | 4 |
undetectable viral | 4 |
trichophyton rubrum | 4 |
estimating fifty | 4 |
attenuated vaccine | 4 |
pulmonary alveoli | 4 |
recombinant fasciola | 4 |
times lower | 4 |
enzymatic active | 4 |
unrelated proteins | 4 |
ip injection | 4 |
particle fraction | 4 |
highly glycosylated | 4 |
rsv exposure | 4 |
labeled secondary | 4 |
nt sirna | 4 |
equal amount | 4 |
iga levels | 4 |
sudlow ii | 4 |
rpmi media | 4 |
weaned mouse | 4 |
zika virus | 4 |
protein lysis | 4 |
dose toxicity | 4 |
jurisdictional claims | 4 |
single administration | 4 |
protein composition | 4 |
previously observed | 4 |
direct contact | 4 |
see current | 4 |
antibody sandwich | 4 |
elisa methods | 4 |
mice vaccinated | 4 |
final manuscript | 4 |
serum sample | 4 |
takes place | 4 |
loading sample | 4 |
betaretroviral dutpase | 4 |
env protein | 4 |
cell ml | 4 |
immunization group | 4 |
volumetric median | 4 |
immunol doi | 4 |
indicated group | 4 |
xg pellet | 4 |
following oral | 4 |
en bloc | 4 |
hinokitiol group | 4 |
four different | 4 |
standard error | 4 |
histological score | 4 |
total igg | 4 |
maternal antibody | 4 |
also confirmed | 4 |
lavage fluid | 4 |
aluminum hydroxide | 4 |
two putative | 4 |
intracellular calcium | 4 |
animal study | 4 |
respiratory diseases | 4 |
mediated immunity | 4 |
macropinocytosis via | 4 |
infected lung | 4 |
available online | 4 |
antiviral immune | 4 |
fujifilm wako | 4 |
protocols article | 4 |
local delivery | 4 |
positive clones | 4 |
specifically inhibits | 4 |
analyzed via | 4 |
adcc activities | 4 |
conservative sites | 4 |
reaction performed | 4 |
sequence similarity | 4 |
may cause | 4 |
pbs washes | 4 |
targeted drug | 4 |
neutral buffered | 4 |
severe ards | 4 |
mm glycine | 4 |
digestive enzymes | 4 |
kidney cells | 4 |
antiviral efficacies | 4 |
cell monolayer | 4 |
virus titration | 4 |
molecular determinants | 4 |
intestinal tissues | 4 |
close contact | 4 |
cervical dislocation | 4 |
virus clearance | 4 |
influenza outbreak | 4 |
pbs fbs | 4 |
important factor | 4 |
similar level | 4 |
progeny virus | 4 |
entry phase | 4 |
expression compared | 4 |
serine protease | 4 |
unpublished data | 4 |
well cluster | 4 |
like type | 4 |
dengue virus | 4 |
activated protein | 4 |
antibodies targeting | 4 |
individual mouse | 4 |
crosslinked human | 4 |
min reaction | 4 |
vector laboratories | 4 |
three major | 4 |
income countries | 4 |
natural antigens | 4 |
healthy controls | 4 |
rapid development | 4 |
deformed wing | 4 |
particles ml | 4 |
laboratory tests | 4 |
highest level | 4 |
eluted fractions | 4 |
genome sequence | 4 |
lung disease | 4 |
whether igf | 4 |
producing escherichia | 4 |
lsm confocal | 4 |
hcl ph | 4 |
kg day | 4 |
sa treatment | 4 |
semithin sections | 4 |
peroxidase substrate | 4 |
sm immunized | 4 |
adcc effect | 4 |
different concentrations | 4 |
million years | 4 |
gfp nps | 4 |
plates three | 4 |
first row | 4 |
infection models | 4 |
surface protein | 4 |
transgenic mice | 4 |
may still | 4 |
immunofluorescence microscopy | 4 |
immune cell | 4 |
anisakis simplex | 4 |
none survived | 4 |
preimmune serum | 4 |
vivo human | 4 |
protein agglutination | 4 |
nh cl | 4 |
passive immunity | 4 |
chicken embryos | 4 |
cellular proteins | 4 |
laboratory pageia | 4 |
gave rise | 4 |
subsequent analysis | 4 |
dansyl asparagine | 4 |
using gene | 4 |
intestinal immune | 4 |
mouse monoclonal | 4 |
intramuscular route | 4 |
phylogenetic relationships | 4 |
antigen preparation | 4 |
short time | 4 |
expressing dpp | 4 |
culture plates | 4 |
peak detection | 4 |
infected larvae | 4 |
light scatter | 4 |
jaagsiekte sheep | 4 |
capture antibody | 4 |
recognize stx | 4 |
preclinical animal | 4 |
piglets administered | 4 |
human colostrum | 4 |
nm diameter | 4 |
also contribute | 4 |
enhanced immune | 4 |
strict accordance | 4 |
jcdv early | 4 |
subsequent booster | 4 |
recorded using | 4 |
recombinant protein | 4 |
dextran uptake | 4 |
buffer ph | 4 |
substantial number | 4 |
trypan blue | 4 |
gave similar | 4 |
lakes nj | 4 |
hematology analyzer | 4 |
macropinocytic entry | 4 |
viral membrane | 4 |
dodecyl sulfate | 4 |
ind route | 4 |
procyte dx | 4 |
demonstrated significantly | 4 |
sequence identity | 4 |
across samples | 4 |
pharmaceutical co | 4 |
immunized animals | 4 |
mass spectrometer | 4 |
differentially expressed | 4 |
ldng uptake | 4 |
also reduced | 4 |
relative humidity | 4 |
mice displayed | 4 |
spotting concentration | 4 |
infect human | 4 |
optimal concentration | 4 |
hallmark inhibitor | 4 |
proteins interacting | 4 |
tissue autofluorescence | 4 |
model control | 4 |
equine encephalitis | 4 |
well using | 4 |
mounted onto | 4 |
spot morphology | 4 |
fasciola cathepsins | 4 |
genomic sequence | 4 |
systematic review | 4 |
antibody library | 4 |
inactivated pv | 4 |
inflammatory diseases | 4 |
rubisco antiserum | 4 |
blocking effect | 4 |
may reflect | 4 |
independent replicates | 4 |
skin lesion | 4 |
virus treated | 4 |
ip buffer | 4 |
survival curves | 4 |
mounting medium | 4 |
various blocking | 4 |
immunological detection | 4 |
lung titers | 4 |
bradford assay | 4 |
series stacks | 4 |
primer sequence | 4 |
veterinary office | 4 |
low level | 4 |
cytokine profile | 4 |
randomly assigned | 4 |
lost approximately | 4 |
gas exchange | 4 |
different fungi | 4 |
egfp fluorescence | 4 |
time course | 4 |
animal use | 4 |
mm sodium | 4 |
number eu | 4 |
expression plasmid | 4 |
perfusion regions | 4 |
reporter mice | 4 |
igg ratio | 4 |
porcine epidemic | 4 |
animals administered | 4 |
superiore di | 4 |
simple method | 4 |
cov spike | 4 |
penicillin streptomycin | 4 |
induce specific | 4 |
low affinity | 4 |
negative mutants | 4 |
following initial | 4 |
severe cases | 4 |
mice lost | 4 |
purified mab | 4 |
pilot study | 4 |
inflammatory bowel | 4 |
sample collection | 4 |
protein sample | 4 |
imaging protocol | 4 |
tata boxes | 4 |
kinase activity | 4 |
single chip | 4 |
nanoparticle delivery | 4 |
enter cells | 4 |
also possible | 4 |
large vesicles | 4 |
western blots | 4 |
group mice | 4 |
infection using | 4 |
free cattle | 4 |
phylogenetic analysis | 4 |
helicobacter pylori | 4 |
infectious dose | 4 |
using previously | 4 |
xg minutes | 4 |
onto nitrocellulose | 4 |
toad sera | 4 |
bacterial pneumonia | 4 |
virus propagated | 4 |
median diameter | 4 |
culture infective | 4 |
matrix protein | 4 |
neutrophil extravasation | 4 |
block tm | 4 |
next investigated | 4 |
peromyscus maniculatus | 4 |
enzyme immunoassay | 4 |
nanoparticle samples | 4 |
charles river | 4 |
human breast | 4 |
commons attribution | 4 |
last accessed | 4 |
newborn piglets | 4 |
leukocyte recruitment | 4 |
last injection | 4 |
early stage | 4 |
large evs | 4 |
lethal challenge | 4 |
th hour | 4 |
human sera | 4 |
death due | 4 |
genes tested | 4 |
light microscope | 4 |
serum dilution | 4 |
airway hyperresponsiveness | 4 |
much less | 4 |
complete inhibition | 4 |
coli bl | 4 |
experiment gave | 4 |
photosynthetic rate | 4 |
protein inhibition | 4 |
induced proliferation | 4 |
exogenous antigens | 4 |
histological examination | 4 |
suckling mice | 4 |
springer nature | 4 |
host endosomal | 4 |
tissue plasminogen | 4 |
cell survival | 4 |
known protein | 4 |
pulmonary artery | 4 |
initial screening | 4 |
recombinant flid | 4 |
cell cytotoxicity | 4 |
species assemblage | 4 |
using primers | 4 |
sterile phosphate | 4 |
export mechanism | 4 |
data set | 4 |
chitin beads | 4 |
alkaline phosphatase | 4 |
severe lung | 4 |
hoc tests | 4 |
substrate solution | 4 |
intratracheal hinokitiol | 4 |
medicine compatibility | 4 |
renilla luciferase | 4 |
rfhpcl elisas | 4 |
therapeutic treatment | 4 |
delivery vehicles | 4 |
type cytokines | 4 |
mediating antibodies | 4 |
influenza vaccination | 4 |
pcr amplification | 4 |
inactivated sars | 4 |
ca mg | 4 |
mucosal surface | 4 |
emerging viruses | 4 |
mannose receptor | 4 |
effective treatment | 4 |
conjugated drug | 4 |
red fluorescence | 4 |
inducible dyna | 4 |
parvum igg | 4 |
myosin ii | 4 |
spect signal | 4 |
oral lactobacillus | 4 |
global burden | 4 |
different strains | 4 |
ne activity | 4 |
scan analysis | 4 |
compatibility principle | 4 |
initial evidence | 4 |
previous findings | 4 |
relative gene | 4 |
gag gene | 4 |
pfizer monkey | 4 |
apical layer | 4 |
delivery applications | 4 |
post hoc | 4 |
whatman paper | 4 |
representative images | 4 |
induced acute | 4 |
five per | 4 |
mediated adcc | 4 |
expression plasmids | 4 |
coronavirus infections | 4 |
staphylococcal protein | 4 |
start codon | 4 |
lysate combination | 4 |
related proteins | 4 |
mm dtt | 4 |
working solution | 4 |
immunity induced | 4 |
maternal immunisation | 4 |
polymeric immunoglobulin | 4 |
molecular weights | 4 |
animals treated | 4 |
pivotal role | 4 |
campylobacter shedding | 4 |
containing multiple | 4 |
accessed april | 4 |
basic cellular | 4 |
survival advantage | 4 |
gb ky | 4 |
unless otherwise | 4 |
grayscale analysis | 4 |
incubation times | 4 |
slightly lower | 4 |
gondii infection | 4 |
independent antiviral | 4 |
pref immunization | 4 |
bowel disease | 4 |
viable cells | 4 |
cells without | 4 |